Daiichi Sankyo makes $10M down payment on cancer drug

Japanese drugmaker Daiichi Sankyo has taken the next step to license a kinase inhibitor dubbed ARQ 092 from U.S. drug developer ArQule ($ARQL), paying $10 million initially in the deal that could be worth as much as $265 million, Mass High Tech reported. Woburn, MA-based ArQule said that the drug is the first one stemming from its 2008 deal with Daiichi to use ArQule's technology to find small-molecule kinase inhibitors. The drug is expected to undergo initial testing in cancer patients in the coming months. Article

Suggested Articles

Biogen will develop a gene therapy with the goal of preserving and possibly restoring vision in patients with PRPF31-mutated retinitis pigmentosa.

A month after moving its COVID-19 antibody cocktail into human trials, Regeneron is testing the drug's ability to ward off COVID-19 infection.

Short reports are nothing new, but the aggressive “I’m coming after you” PR from Applied Therapeutics certainly is.